Name: stem-cell based engineered immunity against hiv infection in the humanized mouse model
Uploaded: 2016-07-02T13:00:00.000+00:00
Duration: 11 min 38 s
Description: Watch this Scientific Journal Video about Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model at JoVE.com

We would like to thank Ms. Jessica Selander in providing artistic assistant in making our figures. This work was funded by grants from the NIAID/NIH, grant no. RO1AI078806, the UCLA Center for AIDS Research (CFAR), grant no. P30AI28697, the California Institute for Regenerative Medicine, grant no. TR4-06845, the American Federation for AIDS Research (amfAR), grant no. #108929-54-RGRL, and the UC Multi-campus Research Program and Initiatives, California Center for Antiviral Drug discovery (CCADD)

伦理声明:人类胎儿组织是从高级Biosciences的资源或从Novogenix获得并未经识别信息，不需要为它的使用的IRB批准得到。在这个手稿中描述的动物研究是加州大学洛杉矶分校和分校（UCLA）的动物研究委员会（ARC）的按照所有联邦，州和地方的指导方针书面同意下进行。具体来说，这些研究是在严格按照该指南的关怀和全国研究委员会实验动物的使用和认可，并为实验动物的评估和认可委员会（AALAC）协会的指导原则中的指导原则进行国际加州大学洛杉矶分校在ARC协议编号2010-038-02B。所有手术均在氯胺酮/甲苯​​噻嗪和异氟醚麻醉下进行并作出一切努力，以尽量减少动物的痛苦和不适。 1.人性化小鼠的构建CD4嵌合抗原受体工程化<ol><li> 处理胎儿胸腺和胎肝隔离CD34 +造血干细胞 <ol><li> 胸腺处理 <ol><li>轻轻洗磷酸盐缓冲盐水（PBS），pH值7.4，胸腺在15ml锥形管中。重复洗涤步骤3 - 4倍。 </li><li>添加7毫升RPMI培养基+ 10％FBS +青霉素/链霉素。倒出一切进入无菌百毫米培养皿。 </li><li>使用解剖刀到胸腺切成小块的约1mm 2。放置在单个井的每一个胸腺片在96孔板中。利用转印胸腺件到96孔板时弯曲的钝钳。 <ol><li>的媒体少量添加（100 - 200微升）到所有的孔中，使得所述组织不干燥。显微镜下可视化（thymi有裂片应该像细胞的麻袋）。 注:放弃以任何方式看起来可疑的任何部分;常常有结缔组织和这不应该被植入。 </li></ol></li><li>取下证实胸腺件，并将它们全部进入T25细胞培养瓶中。新增7毫升补充有10％FBS的RPMI培养基和450微克/毫升哌拉西林/三唑巴坦和两性霉素B轻轻岩石烧瓶以混合。培养在37ºC/ 5％CO 2的烧瓶中过夜。 注:需要这个步骤，以防止组织的细菌污染。 </li><li> （可选步骤）冷冻以供将来使用胸腺。平衡用10％二甲亚砜（DMSO）中的90％人AB血清的组块10分钟。以1ºC/分钟的速率到-50ºC，然后快速冷却到-150ºC冷冻。当准备解冻，解冻迅速在37ºC水浴在RPMI完全培养基轻轻地洗3次无DMSO。 </li></ol></li><li> 肝脏处理 <ol><li>轻轻洗肝在PBS在50毫升锥形管中。重复洗涤步骤3 - 4倍。 </li><li>加入10毫升（Iscove氏修改的Dulbecco氏媒体）的IMDM培养基的50ml锥形管中。倒出一切都变成100毫米的无菌培养皿。 </li><li>均质化使用两个手术刀肝组织。割肝小块约3mm 2。剪下并丢弃任何白色的结缔组织。 </li><li>使用10个毫升注射器配有一个16号钝针占用肝片和媒体。然后转移到50毫升锥形管中。 </li><li>轻轻重悬媒体和组织悬架和驱逐5-7次完全均匀的组织。 </li><li>制备出10毫升的IMDM培养基补充有酶:500U / ml胶原酶2400单位/毫升hyluronidase，和300 U / ml的DNA酶以及450微克/毫升哌拉西林/三唑巴坦和两性霉素B通过一个0.22微米的过滤器过滤介质，然后媒体添加到肝脏停牌。 </li><li>帽含有肝悬浮液的50ml锥形管中并用自密封膜，如石蜡膜Ť封紧Ø防止泄漏。旋转在培养箱试管旋转器在37ºC90分钟。 </li><li>过滤通过100微米的细胞滤网消化的细胞悬液到一个新的50ml管中。 注:加入的PBS悬浮液中，使总体积达50毫升分成各含25 ml的细胞悬浮液50ml试管的两个管这一点。 </li><li>慢慢地和轻轻下垫细胞每管10毫升密度离心介质（ 如，聚蔗糖）。转速为1200 XG 20分钟不带刹车。注意:在这个协议中提到的所有离心是在室温（25℃）进行。 </li><li>小心地从每管和传输接口（ 即 ，血沉棕黄层），以两个独立的50ml试管。带来的接口的每个管的体积至50ml用PBS。旋转300 XG 7 - 10分钟。小心吸上清。 </li><li>将二者结合起来的颗粒。用含2％FBS的50毫升PBS洗三次。旋转300 XG 7 - 10米每次在同时认真吸取上清液。 </li><li>重悬在50ml RPMI培养基+ 10％FBS沉淀。在进行细胞分选之前计数使用血球此时细胞。 </li><li>排序CD34 +细胞立即用CD34排序试剂盒（ 例如 ，CD34微珠），根据制造商的协议。 注:可替代地，细胞可以在RPMI培养基+ 10％FBS 100万过夜培养/ ml的。 </li><li>节省CD34 + CD34-和分数。 注:在这一步骤中，CD34 +和CD34-的细胞可以使用Bambanker冷冻介质或其它冷冻媒体被冻结。冻结1毫升4-的-每管6×10 6个 CD34 +细胞，并冷冻加入1ml 40 -每管60×10 6个 CD34 -细胞。 </li></ol></li></ol></li><li> CD34 +细胞转导 <ol><li>计算6孔组织培养板的所需转导井的数量。 1以及可用于转导至8×10 6个细胞。对于各BLT鼠标，0.5×10 6个 CD34 +将与CD34-细胞和肾囊下胸腺和0.5×10 6个 CD34 +细胞一起被植入将静脉内注射。 CD34 +细胞使用的数量是由小鼠（每鼠标1百万个细胞）的数目来确定。 </li><li>涂层的非组织培养的孔的所需要的数处理6孔板1.25 ml重组人纤连蛋白溶液（ 例如 ，Retronectin进行）（20微克/ ml，在PBS中）到每个孔中。覆盖板，并允许它放置在室温下2小时在一个干净的生物安全柜中。 </li><li>从井抽吸纤连蛋白溶液，并添加1.25毫升FACS缓冲液（PBS中的4％FBS）到每个孔用于阻断。允许该板在室温下（25℃）放置30分钟。 </li><li>吸FACS缓冲液和洗涤液井一次，用PBS。 </li><li>保持的PBS中包被的孔，直到该板是准备使用。在4ºC存储板过夜如果不立即使用。 </li><li>板CD34 +细胞在感染培养基（2％人血清白蛋白在Yssel的无血清T细胞培养基）中纤连蛋白溶液包被的孔（〜2×10 6个细胞/ ml）孵育37ºC1小时。 </li><li>使用移液管，以于感染复数（MOI）之间慢病毒载体添加至孔2 - 10轻轻地混合，并在37ºC孵育过夜。 注意:使用的慢病毒载体的效价应预先确定。 </li><li>通过用细胞刮刀轻轻刮孔的底部收集细胞，第二天早晨。收集细胞并用此时血球计数。 </li><li>为了制备细胞植入物，以每只小鼠，等分试样4.5×10 6个 CD34 -细胞结合0.5×10 6个转导的CD34 +细胞进入无菌1.5毫升螺丝帽试管中。旋转细胞下来300 XG沉淀其中，吸上清。在300 XG再次旋转它们，使用P10吸管吸任何剩余的上清液并且吸取非常CArefully。保持冰的干燥颗粒在整个研究。注:为了确保细胞是可行的，使用沉淀的细胞和2-3小时内进行手术。 </li><li>为了准备细胞注射，旋转0.5×10 6每只小鼠转CD34 +细胞沉淀其中，吸上清。重悬在每鼠标100微升RPMI媒体细胞保持在冰上。 </li><li>签转导效率，等分试样〜1×10 5非转导，并从在200μl细胞因子培养基（RPMI培养基含10％FBS的每个条件和培养转导的CD34 +细胞，补充有100纳克/ ml人IL-3，IL-6的，SCF）中进行5 96孔板 - 7天37ºC。 注意:在这个步骤中使用的细胞不用于手术，但可以确保转导是成功的，该载体是无毒性干细胞存活和更新。转导效率可以通过寻找该载体的基因表达进行检查（ 例如 ，绿色荧光蛋白与CD4）并通过流式细胞术分析。 </li></ol></li><li> 组织移植构建遗传工程小鼠 <ol><li>就在同一天手术前进行NOD.Cg- PRKDC SCID IL2RG牛逼m1Wjl / SZJ（NSG）免疫受损的小鼠与铯-137辐射器和2.7戈瑞（270Rad）的剂量全身照射。 注:核供应国集团小鼠是严重免疫。因此，他们的住房和维护必须符合最高标准的健康和训练有素的工作人员处理。 </li><li>从倒入烧瓶胸腺片和中成60毫米的菜。倾PBS到另一个60mm培养皿，将用于清洁套管针并保持肾湿。 </li><li>通过将它们放置在开1.5毫升无菌螺丝帽管上的冰浴容积枪头。保持与干燥的细胞沉淀和胶状蛋白质混合物如基质胶的冰。 注:保持胶状蛋白质混合物和任何管或提示是很重要的直到留置针装入将触摸它的冷在任何时候。 </li><li>麻醉小鼠:单独称量小鼠和记录的权重;耳冲小鼠数点。氯胺酮的15微升（2.6毫克/毫升在盐水中）/赛拉嗪每克体重（100毫克/盐水中毫升））腹膜内注射它们。把老鼠放回笼子里，等待它被完全麻醉。 注:通过挤压爪子检查鼠标的麻醉水平。如果鼠标本能退缩，辖氯胺酮/甲苯​​噻嗪的原始量的25-50％，进一步麻醉小鼠。等到它不退缩条件反射来进行手术。 </li><li>使用奥斯特削波器（剃须刀），从臀部剃每只小鼠的左侧的背部和腹部的中心之间承担。注入皮下0.3毫升稀释卡洛芬（6毫克/千克）到动物的肩膀或腹股沟三角（腿窝）。用棉签，把人工泪液一小滴到每只眼睛和侧放鼠标回到笼子里。 注:限制手术准备一个笼子 - 在同一时间（约4 5只）。 </li><li>冲洗16号癌植入针（套管针），用PBS的插管。使用一对钝弯钳，放置从60毫米的菜一块胸腺入套管与套管刚刚开口内开幕，再拉回来的套管针的组织吸进套管。 </li><li>使用正位移移液器和冷藏尖把5微升冷凝胶状蛋白混合物进入管干细胞团（CD34 + CD34-和混合物植入的细胞），并轻轻搅动产生细胞悬液。不要移液器上下。吸取胶状蛋白质混合物/细胞悬液到套管的开口和慢慢拉回来的套管针加载针。 注:建议有一个助手来加载吸管而一个操纵留置针。 </li> &lt;利&gt;拭鼠标的剃区域用聚维酮碘，随后的擦平与醇的区域擦拭三次。确定皮肤下的最黑暗的地方。这表明脾脏的位置。肾是约5mm背侧脾脏。抬起与弯钳皮肤并与平行于脾皮肤手术剪15毫米长的切口。然后作出类似的削减腹膜下方层。在男性中，肾应该很容易可见的，并且可以通过按压上腹部简单地挤出。可以支持用止血钳或一对弯曲钝钳的肾。在女性，卵巢往往会阻止从易提取肾脏。用止血钳，拿起卵巢并仔细暴露出来的肾脏。 </li><li>使用针尖镊子在肾囊的后端掐一个微小的孔。 注意:不要使用这些针尖镊子处理生物危害的材料。 </li><li>滑动植入针插入该孔并沿着肾脏直到套管的开口完全被肾囊所覆盖。 </li><li>轻轻挤压肾囊下的组织，并拔出针​​退了出去。胸腺片可粘所以用一个弯钳以确保胸腺片不与针出来。 </li><li>抬起用钳子腹膜，轻轻用止血钳推肾脏回原位。使用4-0薇乔可吸收缝线腹膜领带一张双人床打结针。使用两个Autoclips伤口剪辑关闭皮肤。 </li><li>混合被预留用于注射该被转导的CD34 +细胞和摄取100微升（0.5×6个细胞）进胰岛素注射器。注入这些细胞进入通过眶后静脉注射或静脉注射的其他途径的鼠标。用棉签，把人工泪液一小滴在每个眼睛，躺在鼠标在其一侧回来关在笼子里。 </li><li>一旦所有的小鼠都bEEN植入，确认该动物苏醒，离开他们面前走动正常。 </li><li>后操作方式:在手术后的第二天，皮下注入0.3毫升稀释卡洛芬（6毫克/千克）和1.2毫升无菌的生理盐水到每只小鼠。图2和3天后手术，皮下注入1.5毫升无菌盐水到每只小鼠。监测小鼠和手术后10-14天的切口。除去Autoclips和后10-14天称量小鼠。注:小鼠不畅辐射和生理盐水注射防止脱水变成动物后。 </li><li> 8后 - 10周放血小鼠和外周血进行FACS分析，染色标记如CD45，CD3，CD4，CD8和载体应表达任何基因检查植入。 </li></ol></li></ol> 2.分化的表征和基因修饰细胞的发育<ol><li> 表征从外周血基因修饰细胞<ol><li> 8 - 从眼眶出血100微升小鼠血 - 移植10周后，获得50。在含10微​​升EDTA的离心管的地方。离心细胞，在350×g离心3分钟。收集血浆。在-80用于ELISA分析或血浆病毒载量检测冻结如果鼠标是艾滋病感染者。 </li><li>加2ml 氯化铵 （83％）溶液以裂解红血细胞。孵育在室温（25℃）5分钟。孵育后，加入10 mL RPMI 10％FBS，以填补管。旋在300×g离心5分钟。小心吸上清。细胞准备用于免疫染色和流式细胞仪分析等测定。 注:关于各种造血细胞谱系，活化，以及用于幼稚或记忆细胞表型标志物标记可以每2周前和HIV感染通过流式细胞后进行测量。盖茨是通过染色细胞的同型对照创建。它建议以染色healtHY人PBMC和使用，作为阳性对照。或者，鼠标可以安乐死和至多1毫升外周血可以从心脏穿刺将用于流分析17的多个面板提供足够的细胞而获得。 </li></ol></li><li> 脾脏，胸腺，骨髓基因鉴定修饰细胞 <ol><li> 收获脾脏，胸腺和骨髓从人性化的BLT小鼠 <ol><li>通过使用异氟醚过量安乐死小鼠。确认继发颈椎脱位安乐死。喷用70％乙醇的胎体的表面，以保持皮毛粘到组织中。牵制在解剖蜡盘四肢。 </li><li>用手术剪，剖开皮肤，然后通过腹膜层切开，以暴露在体腔内。 </li><li>使用镊子取出脾脏。取出使用镊子和剪刀肾脏胸腺植入物。把植入胸腺和脾脏中标记的试管CONTA进不去5毫升的PBS。 </li><li>从中间腹部切割并从小鼠覆盖下肢的末端部分去除皮肤。 </li><li>切断由下肢肌肉用剪刀，小心地从脱位髋关节髋臼。取出股骨和胫骨，并将其放置于含有5毫升的PBS的管。 </li></ol></li><li> 脾细胞的分离 <ol><li>放置在50ml锥形管中的100微米的细胞滤网。湿用3ml RPMI培养基中补充有10％FBS和青霉素/链霉素（RPMI完全培养基）的过滤器。 </li><li>放置脾到细胞过滤。使用10毫升注射器中的橡胶柱塞，捣碎脾通过过滤器，以分离入50ml管中。 </li><li>冲洗用5毫升的RPMI完全培养基4至5倍的细胞过滤网。 </li><li>旋转细胞以300×g离心10分钟。 </li><li>吸上清，重悬沉淀在5ml红细胞裂解缓冲液。孵育在室温彩画TURE 10分钟。在300 xg离心加20毫升RPMI完全培养基和旋转7分钟。 </li><li>抽吸上清液，并在10毫升的RPMI完全培养基重悬沉淀，并通过100微米的细胞滤网再次进行过滤。使用血细胞计数器细胞。 注:细胞可用于体外测定法，流动分析，并且可以可行地冷冻供以后使用。细胞计数之前，台盼蓝可用于确定存活细胞的数量。 </li></ol></li><li> 从植入人体胸腺细胞的分离 <ol><li>放置胸腺到5毫升的PBS在6孔板的孔中。使用清洁钝钳和剪刀剪胸腺小块。 </li><li>将消毒的不锈钢网方入井。使用10毫升注射器中的橡胶柱塞，捣碎在不锈钢丝网胸腺件掰开胸腺。 </li><li>重悬细胞井和应变通过100微米的细胞滤网。旋转细胞以300×g离心10分钟。暂停在10毫升RPMI完全培养基中的细胞。如果团块可见，再次通过悬浮细胞通过细胞过滤。 </li><li>使用血细胞计数器细胞。 注:细胞可用于流分析和可行地冷冻供以后使用。 </li></ol></li><li> 从骨髓细胞的分离 <ol><li>清洁和消毒砂浆并用70％的乙醇杵。放置股骨和胫骨成砂浆。加入5毫升冷的PBS。使用杵粉碎的骨头，直到PBS变为淡粉色，多云。 </li><li>吸取从砂浆和过滤器中的流体通过放置在50ml锥形管中的50微米的细胞滤网。用5毫升PBS洗涤砂浆，重复五次，直到PBS变得清晰。 </li><li>旋转细胞向下在300×g离心7分钟。吸上清，重悬在10毫升的RPMI完整的媒体。 </li><li>使用血细胞计数器细胞。 注:细胞可用于体外测定法，流动分析，并且可以是可行地冷冻˚F或以后使用。 </li></ol></li></ol></li></ol> 3.基因修饰细胞功能研究<ol><li> 艾滋病毒感染和病毒复制随着时间的推移监控 <ol><li>人体免疫系统重建的确认后，通过使用胰岛素注射器眼眶静脉注射注入HIV病毒所需的量。 HIV感染后，经眼眶出血，每2周收集100微升外周血。 </li><li>收获血浆以下部分2.1.1步骤 - 2.1.2。对于HIV病毒负荷测定中，使用根据制造商的指导RNA提取试剂盒提取病毒RNA，并测量通过实时RT-PCR检测病毒载量与合适的引物和探针组用于4,8,18,19 HIV病毒。 </li><li>为了测量细胞相关的HIV RNA并识别正在积极受艾滋病毒感染的细胞，先执行以下步骤2.1.2 RBC裂解</li><li>在1悬浮细胞悬液;毫升的PBS，均匀地划分成两个管。旋在300×g离心5分钟。吸上清。 </li><li>为了测量细胞相关的RNA，提取使用RNA RNA提取试剂盒根据制造商的指令，并使用合适的引物和探针组进行实时RT-PCR法。 注:该引物/探针不能识别用于修饰干细胞的慢病毒是非常重要的</li><li>以测量的HIV流动感染细胞，悬浮细胞在另一管在50μlFACS缓冲液，并与如抗CD45，抗CD4和抗CD3所需抗体进行表面染色。表面染色后，修复和使用抗Gag的抗体（克隆KC57）通透细胞和细胞内染色的插科打诨的表达。执行流式细胞仪。 </li></ol></li><li> 基因体外细胞因子检测修饰细胞从脾 <ol><li>从小鼠脾细胞收获如第2.2.2所述。 </li><li>准备靶细胞。为了测试功能CD4嵌合抗原受体修饰的T细胞性，用HIV感染T1细胞作为靶细胞。感染的T1细胞与HI​​V前3天的细胞因子测定法中，通过用抗HIV的gag抗体（克隆KC57）细胞内染色细胞证实HIV感染。使用未感染细胞T1作为对照靶细胞。 </li><li> 1共孵育的目标或控制的脾细胞:1的比例过夜。对于最好的结果，进行滴定（1:1，1:3,1:9）的效应的（脾细胞）对靶细胞（感染的T1）。例如，重悬90万脾于0.25ml RPMI完整的媒体，加入悬浮于0.25ml RPMI完整的媒体0.9，0.3或0.1万受感染的T1或未受感染的T1线路。 </li><li>第二天早上，添加蛋白转运抑制剂6小时，以抑制蛋白质的运输和进行染色细胞外标记和如在8先前所述细胞因子的胞内表达。 </li></ol></li></ol>

<ol>
	<li>Karpel, M. E., Boutwell, C. L., Allen, T. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=BLT+humanized+mice+as+a+small+animal+model+of+HIV+infection.">BLT humanized mice as a small animal model of HIV infection.</a> Current opinion in virology. 13, 75-80 (2015).</li><li>Zhen, A., Kitchen, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Stem-cell-based+gene+therapy+for+HIV+infection.">Stem-cell-based gene therapy for HIV infection.</a> Viruses. 6 (1), 1-12 (2014).</li><li>Goulder, P. J. R., Watkins, D. I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=HIV+and+SIV+CTL+escape:+implications+for+vaccine+design.">HIV and SIV CTL escape: implications for vaccine design.</a> Nature Reviews: Immunology. 4 (8), 630-640 (2004).</li><li>Kitchen, S. G., Bennett, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Engineering+Antigen-Specific+T+Cells+from+Genetically+Modified+Human+Hematopoietic+Stem+Cells+in+Immunodeficient+Mice.">Engineering Antigen-Specific T Cells from Genetically Modified Human Hematopoietic Stem Cells in Immunodeficient Mice.</a> PloS one. 4 (12), e8208 (2009).</li><li>Goulder, P. J. R., Watkins, D. I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=HIV+and+SIV+CTL+escape:+implications+for+vaccine+design.">HIV and SIV CTL escape: implications for vaccine design.</a> Nature Reviews: Immunology. 4 (8), 630-640 (2004).</li><li>Kitchen, S. G. S., Levin, B. R. B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=In+vivo+suppression+of+HIV+by+antigen+specific+T+cells+derived+from+engineered+hematopoietic+stem+cells.">In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells.</a> PLoS Pathogens. 8 (4), e1002649 (2012).</li><li>Yang, O. O., Tran, A. C., Kalams, S. A., Johnson, R. P., Roberts, M. R., Walker, B. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lysis+of+HIV-1-infected+cells+and+inhibition+of+viral+replication+by+universal+receptor+T+cells.">Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells.</a> PNAS. 94 (21), 11478-11483 (1997).</li><li>Zhen, A., Kamata, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=HIV-specific+Immunity+Derived+From+Chimeric+Antigen+Receptor-engineered+Stem+Cells.">HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells.</a> Molecular Therapy. 23 (8), 1358-1367 (2015).</li><li>Barrett, D. M., Singh, N., Porter, D. L., Grupp, S. A., June, C. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Chimeric+Antigen+Receptor+Therapy+for+Cancer.">Chimeric Antigen Receptor Therapy for Cancer.</a> Annual Review of Medicine. 65 (1), 333-347 (2014).</li><li>Pejchal, R., Doores, K. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+Potent+and+Broad+Neutralizing+Antibody+Recognizes+and+Penetrates+the+HIV+Glycan+Shield.">A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield.</a> Science. 334 (6059), 1097-1103 (2011).</li><li>Caskey, M., Klein, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Viraemia+suppressed+in+HIV-1-infected+humans+by+broadly+neutralizing+antibody+3BNC117.">Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.</a> Nature. 522 (7557), 487-491 (2015).</li><li>West, A. P., Scharf, L., Scheid, J. F., Klein, F., Bjorkman, P. J., Nussenzweig, M. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Structural+insights+on+the+role+of+antibodies+in+HIV-1+vaccine+and+therapy.">Structural insights on the role of antibodies in HIV-1 vaccine and therapy.</a> Cell. 156 (4), 633-648 (2014).</li><li>Lan, P., Tonomura, N., Shimizu, A., Wang, S., Yang, Y. -. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Reconstitution+of+a+functional+human+immune+system+in+immunodeficient+mice+through+combined+human+fetal+thymus/liver+and+CD34++cell+transplantation.">Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation.</a> Blood. 108 (2), 487-492 (2006).</li><li>Melkus, M. W., Estes, J. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Humanized+mice+mount+specific+adaptive+and+innate+immune+responses+to+EBV+and+TSST-1.">Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1.</a> Nature medicine. 12 (11), 1316-1322 (2006).</li><li>Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V., Greiner, D. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Humanized+mice+for+immune+system+investigation:+progress,+promise+and+challenges.">Humanized mice for immune system investigation: progress, promise and challenges.</a> Nature Reviews: Immunology. 12 (11), 786-798 (2012).</li><li>Vatakis, D. N., Bristol, G. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Using+the+BLT+humanized+mouse+as+a+stem+cell+based+gene+therapy+tumor+model.">Using the BLT humanized mouse as a stem cell based gene therapy tumor model.</a> Journal of visualized experiments : JoVE. (70), e4181 (2012).</li><li>De Rosa, S. C., Brenchley, J. M., Roederer, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Beyond+six+colors:+a+new+era+in+flow+cytometry.">Beyond six colors: a new era in flow cytometry.</a> Nature medicine. 9 (1), 112-117 (2003).</li><li>Shimizu, S., Hong, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+highly+efficient+short+hairpin+RNA+potently+down-regulates+CCR5+expression+in+systemic+lymphoid+organs+in+the+hu-BLT+mouse+model.">A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.</a> Blood. 115 (8), 1534-1544 (2010).</li><li>Denton, P. W., Olesen, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Generation+of+HIV+latency+in+humanized+BLT+mice.">Generation of HIV latency in humanized BLT mice.</a> Journal of virology. 86 (1), 630-634 (2012).</li><li>Zhou, J., Zhang, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Embryoid+bodies+formation+and+differentiation+from+mouse+embryonic+stem+cells+in+collagen/Matrigel+scaffolds.">Embryoid bodies formation and differentiation from mouse embryonic stem cells in collagen/Matrigel scaffolds.</a> Journal of Genetics and Genomics. 37 (7), 451-460 (2010).</li><li>Vatakis, D. N., Arumugam, B., Kim, S. G., Bristol, G., Yang, O., Zack, J. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Introduction+of+Exogenous+T-cell+Receptors+Into+Human+Hematopoietic+Progenitors+Results+in+Exclusion+of+Endogenous+T-cell+Receptor+Expression.">Introduction of Exogenous T-cell Receptors Into Human Hematopoietic Progenitors Results in Exclusion of Endogenous T-cell Receptor Expression.</a> Molecular Therapy. 21 (5), 1055-1063 (2013).</li><li>Ito, R., Takahashi, T., Katano, I., Ito, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Current+advances+in+humanized+mouse+models.">Current advances in humanized mouse models.</a> Cellular &amp; Molecular Immunology. 9 (3), 208-214 (2012).</li><li>Martinez-Torres, F., Nochi, T., Wahl, A., Garcia, J. V., Denton, P. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Hypogammaglobulinemia+in+BLT+humanized+mice--an+animal+model+of+primary+antibody+deficiency.">Hypogammaglobulinemia in BLT humanized mice--an animal model of primary antibody deficiency.</a> PloS one. 9 (10), e108663 (2014).</li><li>McCune, J. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Development+and+applications+of+the+SCID-hu+mouse+model.">Development and applications of the SCID-hu mouse model.</a> Seminars in Immunology. 8 (4), 187-196 (1996).</li><li>Srivastava, S., Riddell, S. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Engineering+CAR-T+Cells:+Design+Concepts.">Engineering CAR-T Cells: Design Concepts.</a> Trends in immunology. 36 (8), (2015).</li></ol>

The authors have nothing to disclose.

与汽车和走向临床研究基于HSC工程免疫力蓄势待发，它有一个合适的动物模型来仔细研究这些工程细胞的分化和功能是非常重要的。在这个协议中，我们描述的构建和测试与设计的抗HIV基因修饰的干细胞小鼠人性化的方法。有前移植干细胞的有效转导是重要的。然而，由于T细胞在识别靶细胞增殖的能力，干细胞修饰的低含量足以产生针对HIV复制8健壮响应。 然而，要实现干细胞修饰水平高，我们建议使用转CD34 +细胞与自体胸腺代替肝脏和别处已经13-15描述了小鼠胸腺手术大块胶状蛋白质混合物。胶状蛋白质混合物是solubilizED组织基底膜含有丰富的细胞外基质蛋白。在正常生理条件下，胶状蛋白质混合物聚合，以产生一个复原的，生物活性和稳定的基质，将允许干细胞20的有效附着和分化。人类细胞重建可以通过眼眶后出血检查和流式细胞仪6 - 8周手术后。为了确保载体是没有毒性为干细胞存活和更新，它被推荐为在1.2.6描述的滴度在实验前的CD34 +细胞的载体。 核供应国集团-BLT小鼠模型的能力，支持粘膜感染，病毒血症一致和细胞免疫反应使它成为一个非常有用的模型来研究艾滋病病毒的免疫病理学和细胞疗法来治疗HIV感染1。最重要的是，从NSG-BLT小鼠中产生的T细胞中的自体胸腺组织被选择，使得研究者研究命运的胸腺选择8,21后基因修饰的干细胞。所描述的方法，我们已经能够拿到40％-90％人体免疫细胞重建一致。人类细胞重建的低水平可导致从多个因素，包括在执行外科手术和组织移植的质量的人的技能。实现人细胞重建的水平高，重要的是要保证移植稳固地放置在肾囊下。另外，强烈建议检查光学显微镜下手术准备每个胸腺植入物和丢弃任何可疑的碎片。 虽然人性化的BLT小鼠模型是研究抗HIV免疫力工程（在1,15,22审查）一个行之有效的手段，它有其自身的局限性。即，该模型不完全模仿人末梢的免疫系统。研究表明超突变，类别转换抗体antibo的发育受损DY 1,23。此外，使用免疫缺陷小鼠在技术上具有挑战性，并保持这些小鼠的健康需要大量的资源和培训。微妙的机会性感染可表现在整个样本的差异显著，并可能对实验的消极后果。因此，有充分的准备的设施和经过适当培训的人员来维护未来数据1,24的完整性是非常重要的。考虑到这些限制，人源化NSG-BLT小鼠模型仍然提供了干细胞的基础工程改造的免疫的研究的重要工具，如由这些实施例4,8证实。 与中和抗体10和更有效的汽车25上的信号结构域的修饰基于HIV广泛发展的嵌合抗原受体的趋势，这种模式和协议可以用于表征并调查该基因修饰的CEL的功能LS采用了新一代汽车。此外，该模型可以潜在地容纳在与工程化免疫结合在基于免疫治疗研究（如抑制性受体阻断）。

尽管联合抗逆转录病毒治疗的成功，HIV感染仍然是一个终身疾病。抗HIV细胞免疫反应在控制HIV复制非常重要的作用。在干细胞处理的最新进展已经允许基因治疗的飞速发展途径HIV治疗1-3。其结果是，它有一个适当的动物模型，它允许在抗HIV基于细胞的疗法的效力的体内研究是非常重要的。 在动物模型中与HIV的工作是由一个事实，即病毒只感染人类细胞复杂。为了规避这一限制，科学家们开始借助疾病模型像猕猴4,5猴免疫缺陷病毒（SIV）。不幸的是，在此模型中，由于跨物种的固有差异和SIV和HIV之间的差异主要限制。此外，只有高度专业化的设施是C支持工作，非人类灵长类动物，每个猕猴apable需要大量的投资。因此，为模型中的迫切需要，利用人的免疫系统，这是易受HIV感染/发病机制，并且是较少财政望而却步。 非肥胖糖尿病（NOD） -严重联合免疫缺陷（SCID）-commonγ链基因敲除（三γ - / - ）（或NSG）血液/肝脏/胸腺（BLT）的人源化小鼠模型日益被证明是一个重要的工具以研究艾滋病病毒感染。通过注入的造血干细胞（HSC）以及胎胸腺，小鼠能够开发和概括一个人免疫系统1-3。基于干细胞的基因治疗的一种类型涉及&#39;重定向&#39;的外周T细胞重新编程造血干细胞（HSC）能够分化为抗原特异性T细胞为目标的HIV。我们以前曾表明，工程造血干细胞与分子克隆抗HIV特异性T细胞再受体（TCR）对抗原SL9（氨基酸77-85; SLYNTVATL）HIV-1的Gag可以干细胞重定向到形成的抑制人性化的NSG-BLT小鼠模型6 HIV复制成熟T细胞。使用分子克隆的TCR的需要注意的是，它被限制为特定的人白细胞抗原（HLA）亚型，这将限制这种疗法的应用。嵌合抗原受体（CAR），另一方面，可普遍适用于所有的HLA亚型。进行最初的研究利用具有融合于细胞内ζ信令的CD3域人CD4的细胞外和跨膜结构域构成的汽车（称为CD4ζCAR）。 CD4ζCAR上的CD8 T细胞上表达能够识别HIV包膜并引发细胞毒性T细胞应答是类似于由T细胞受体7介导的。我们最近证明人肝星状细胞可以与CD4ζCAR，然后可以分化成多种造血里进行修改neages，包括能够抑制在人源化小鼠模型8 HIV复制的功能的T细胞。在嵌合抗原受体疗法的快速进步癌症9，和有效的宽的中和抗体10-12抗HIV，允许单链抗体车的结构的持续表征，它是可感知的，许多新的候选构建体，除了CD4ζCAR ，将产生与艾滋病毒和其他疾病的干细胞基于基因疗法试验。另外，含有这些抗原特异性的CARs人源化NSG-BLT小鼠模型也可提供一个有用的工具仔细检查体内人T细胞应答。重要的是，我们的协议不同于先前描述的结构的人源化的BLT小鼠13-15在于，造血干细胞在胶状蛋白质混合物代替胎肝中继线16的使用方法。本协议描述:1）humani建设与CD4ζCAR工程捷思BLT小鼠;和2）的遗传修饰的细胞的分化的表征;和3）的经遗传修饰的细胞的功能性表征。

<table><tbody><tr><td>CD34 microbead kit</td><td>Miltenyi</td><td>130-046-702</td><td>For sorting human CD34+ progenitor cells</td></tr><tr><td>Bambanker</td><td>Wako</td><td>302-14681</td><td>For freezing cells</td></tr><tr><td>QIAamp Viral RNA kit&amp;nbsp;</td><td>Qiagen</td><td>52904</td><td>For measuring viral load in the serum</td></tr><tr><td>MACSQuant Flow Cytometer</td><td>Miltenyi</td><td></td><td>For flow analysis</td></tr><tr><td>BD LSRFortessa&amp;trade;</td><td>BD biosciences</td><td></td><td>For flow analysis</td></tr><tr><td>Hyaluronidase</td><td>Sigma</td><td>H6254-500MG&amp;nbsp;</td><td>For tissue digestion</td></tr><tr><td>Deoxyribonuclease I&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;</td><td>Worthington</td><td>LS002006&amp;nbsp;</td><td>for tissue digestion</td></tr><tr><td>Collagenase</td><td>Life technology</td><td>17104-019&amp;nbsp;</td><td>for tissue digestion</td></tr><tr><td>CFX Real time PCR detection system</td><td>Biorad</td><td></td><td>For measuring viral load and gene expression</td></tr><tr><td>Mice, strain NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ</td><td>The Jackson Laboratory</td><td>5557</td><td>For constructing the humanized mice</td></tr><tr><td>Penicillin Streptomycin (Pen Strep)</td><td>Thermo Fisher Scientific</td><td>10378016</td><td>For culturing cells</td></tr><tr><td>Piperacillin/tazobactam</td><td>Pfizer</td><td>Zosyn</td><td>Anti-fungal</td></tr><tr><td>Amphotericin B (Fungizone antimycotic)</td><td>Thermo Fisher Scientific</td><td>15290-018</td><td>Anti-fungal</td></tr><tr><td>Autoclip Wound Clips, 9 mm - 1,000 units</td><td>Becton Dickinson</td><td>427631&amp;nbsp;</td><td>For surgery</td></tr><tr><td>Sterile Poly-Reinforced Aurora Surgical Gowns, 30 per case&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;</td><td>Medline</td><td>DYNJP2707&amp;nbsp;</td><td>For surgery</td></tr><tr><td>Sutures, 4-0, vicryl&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;</td><td>Owens and Minor</td><td>23000J304H&amp;nbsp;&amp;nbsp;</td><td>For surgery</td></tr><tr><td>Alcohol prep pads&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;</td><td>Owens and Minor</td><td>3583006818</td><td>For surgery</td></tr><tr><td>Gloves, surgical, 6 1/2</td><td>Owens and Minor</td><td>4075711102</td><td>For surgery</td></tr><tr><td>Yssel&amp;rsquo;s Serum-Free T-Cell Medium</td><td>Gemini Bio-products</td><td>400-102</td><td>For CD34+ cell transduction</td></tr><tr><td>Human Serum Albumin&amp;nbsp;</td><td>Sigma-Aldrich</td><td>A9511</td><td>For CD34+ cell transduction</td></tr></tbody></table>

stem-cell based engineered immunity against hiv infection in the humanized mouse model

与基于细胞干基因疗法的快速发展对抗HIV，有迫切要求的用于动物模型来研究所述遗传修饰的细胞的造血细胞分化和免疫功能。人源化的骨髓/肝脏/胸腺（BLT）小鼠模型允许在周围的人的免疫系统，其包括T细胞，B细胞，NK细胞和单核细胞的完整的重建。人胸腺植入物还允许在自体胸腺组织的T细胞的胸腺选择。除了感染艾滋病毒的研究中，模型矗立作为一个强大的工具来研究造血干细胞（HSCs）的细胞的分化，发育和功能。在这里，我们勾勒出人性化的非肥胖型糖尿病（NOD）的建设-严重联合免疫缺陷病（SCID）中的常见γ链基因敲除（Cγ - / - ）-Bone骨髓/肝脏/胸腺（NSG-BLT）小鼠造血干细胞转导与CD4嵌合抗原受体（CD4CAR）慢病毒载体。我们表明，CD4CAR造血干细胞可以成功地分化成多种谱系，并有抗HIV活性。该研究的目的是说明使用NSG-BLT小鼠模型的作为抗HIV工程化免疫的体内模型。值得注意的是，因为慢病毒和人体组织时，实验和手术应该在II级生物安全柜与特殊的预防措施（BSL2 +）设施执行在生物安全等级2（BSL2）。

图1显示了构建具有修饰的干细胞源化的BLT小鼠的轮廓。植入手术10周后，处死小鼠，以评估基因修饰细胞的分化和发育。 如图2中所示，多个淋巴组织（血液，脾，胸腺和骨髓）中从使用CD4ζCAR改性的小鼠收获。在这个协议中使用的CD4ζCAR包含可由抗CD4抗体和GFP 8的表达进行检测的CD4嵌合抗原受体和GFP。细胞分离并用抗人CD45抗体，以及抗CD4抗体染色，并通过流式细胞仪分析。 GFP和CD4双阳性细胞中检测到，这表明CD4CAR +细胞在多种淋巴组织的存在。 调查该基因修饰的细胞的分化，<html>脾细胞与抗人CD45（淋巴细胞），CD3（T细胞），CD19（B细胞），CD14（单核细胞和巨噬细胞）和CD337（NK细胞）抗体染色。正如图3所示，CD4ζCAR造血干细胞分化成多种谱系。 为了研究CD4CAR修饰的细胞功能，我们共孵育与CD4CAR细胞将其识别（HIV感染T1细胞或感染T1细胞作为对照）的靶细胞脾。细胞共温育过夜，并为额外的6小时加入的蛋白转运抑制剂。此后，将细胞固定和透化染色对细胞因子例如IFNγ和TNFα的细胞内表达。如在图4中所示，CAR表达的细胞产生较高量的IFNγ和TNFα的受感染的T1细胞。 负载/ 54048 / 54048fig1.jpg"/&gt; 图1:胎儿胸腺: 建筑与修饰的干细胞人性化的BLT小鼠 FT 纲要 。 FL:胎肝<a href="https://www-jove-com.remotexs.ntu.edu.sg/files/ftp_upload/54048/54048fig1large.jpg" target="_blank">请点击此处查看该图的放大版本。</a> <img alt="图2" src="/files/ftp_upload/54048/54048fig2.jpg" /> 图2:CD4嵌合抗原受体修饰的细胞可以在多种淋巴组织中被检测到小鼠与CD4CAR改性肝星状细胞手术和多个淋巴组织后处死10周收获和细胞染色用抗人CD45和抗人CD4抗体并通过流式细胞仪分析。 <a href="https://www-jove-com.remotexs.ntu.edu.sg/files/ftp_upload/54048/54048fig2large.jpg" target="_blank">请点击此处查看该图的放大版本。</a> 图3:CD4嵌合抗原受体修饰的细胞可以分化成多种谱系从CD4CAR基因小鼠脾细胞收获，并与抗人CD45，CD3，CD19，CD14和CD337抗体染色，并通过流式细胞仪分析<a href="https://www-jove-com.remotexs.ntu.edu.sg/files/ftp_upload/54048/54048fig3large.jpg" target="_blank">请点击这里查看大图版本这个数字。</a> <img alt="图4" src="/files/ftp_upload/54048/54048fig4.jpg" /> 图4:CD4 CAR + T细胞的体外细胞因子测定艾滋病毒感染的脾细胞的小鼠CD4CAR用两种HIV感染或感染T1细胞和细胞内细胞因子的产生显示刺激。 <a href="https://www-jove-com.remotexs.ntu.edu.sg/files/ftp_upload/54048/54048fig4large.jpg" target="_blank">请点击此处争夺</a>WA更大的版本这个数字。

Watch this Scientific Journal Video about Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model at JoVE.com

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

This protocol describes the methods in constructing a humanized bone-marrow/liver/thymus mouse model with stem cell-based engineered immunity against HIV infection.

干细胞基工程免疫抗HIV感染的人性化小鼠模型

With the rapid development of stem cell-based gene therapies against HIV, there is pressing requirement for an animal model to study the hematopoietic ...

stem-cell-based-engineered-immunity-against-hiv-infection-humanized

Nanyang Technological University

Research

JoVE Journal

Medicine

10.1K 次观看.  University of California, Los Angeles. This protocol describes the methods in constructing a humanized bone-marrow/liver/thymus mouse model with stem cell-based engineered immunity against HIV infection. 

视频: Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Using the BLT Humanized Mouse as a Stem Cell based Gene Therapy Tumor Model

Small animal models such as mice have been extensively used to study human disease and to develop new therapeutic interventions. Despite the wealth of information gained from these studies, the unique characteristics of mouse immunity as well as the species specificity of viral diseases such as human immunodeficiency virus (HIV) infection led to the development of humanized mouse models. The earlier models involved the use of C. B 17 scid/scid mice and the transplantation of human fetal thymus and fetal liver termed thy/liv (SCID-hu) 1, 2 or the adoptive transfer of human peripheral blood leukocytes (SCID-huPBL) 3. Both models were mainly utilized for the study of HIV infection.
One of the main limitations of both of these models was the lack of stable reconstitution of human immune cells in the periphery to make them a more physiologically relevant model to study HIV disease. To this end, the BLT humanized mouse model was developed. BLT stands for bone marrow/liver/thymus. In this model, 6 to 8 week old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) immunocompromised mice receive the thy/liv implant as in the SCID-hu mouse model only to be followed by a second human hematopoietic stem cell transplant 4. The advantage of this system is the full reconstitution of the human immune system in the periphery. This model has been used to study HIV infection and latency 5-8.
We have generated a modified version of this model in which we use genetically modified human hematopoietic stem cells (hHSC) to construct the thy/liv implant followed by injection of transduced autologous hHSC 7, 9. This approach results in the generation of genetically modified lineages. More importantly, we adapted this system to examine the potential of generating functional cytotoxic T cells (CTL) expressing a melanoma specific T cell receptor. Using this model we were able to assess the functionality of our transgenic CTL utilizing live positron emission tomography (PET) imaging to determine tumor regression (9).
The goal of this protocol is to describe the process of generating these transgenic mice and assessing in vivo efficacy using live PET imaging. As a note, since we use human tissues and lentiviral vectors, our facilities conform to CDC NIH guidelines for Biosafety Level 2 (BSL2) with special precautions (BSL2+). In addition, the NSG mice are severely immunocompromised thus, their housing and maintenance must conform to the highest health standards (<a href="http://jaxmice.jax.org/research/immunology/005557-housing.html" target="_blank">http://jaxmice.jax.org/research/immunology/005557-housing.html</a>).

The generation and characterization of tumor specific T cells using humanized mice is described here. Human thymic tissue and genetically modified human hematopoietic stem cells are transplanted into immunocompromised mice. This results in the reconstitution of an engineered human immune system allowing for in vivo examination of anti-tumor immune responses.

BLT人性化的鼠标使用一个基于干细胞的基因治疗肿瘤模型的建立

Small animal models such as mice have been extensively used to study human  disease and to develop new therapeutic interventions. Despite the wealth of  ...

科研

免疫与感染

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Reversing the immunosuppressive nature of the tumor microenvironment is critical for the successful treatment of cancers with immunotherapy drugs. Murine cancer models are extremely limited in their diversity and suffer from poor translation to the clinic. To serve as a more physiological preclinical model for immunotherapy studies, this protocol has been developed to evaluate the treatment of human tumors in a mouse reconstituted with a human immune system. This unique protocol demonstrates the development of human immune system (HIS, &#34;humanized&#34;) mice, followed by implantation of a human tumor, either a cell-line derived xenograft (CDX) or a patient derived xenograft (PDX). HIS mice are generated by injecting CD34+ human hematopoietic stem cells isolated from umbilical cord blood into neonatal BRGS (BALB/c Rag2-/- IL2R&#947;C-/- NODSIRP&#945;) highly immunodeficient mice that are also capable of accepting a xenogeneic tumor. The importance of the kinetics and characteristics of the human immune system development and tumor implantation is emphasized. Finally, an in-depth evaluation of the tumor microenvironment using flow cytometry is described. In numerous studies using this protocol, it was found that the tumor microenvironment of individual tumors is recapitulated in HIS-PDX mice; &#34;hot&#34; tumors exhibit large immune infiltration while &#34;cold&#34; tumors do not. This model serves as a testing ground for combination immunotherapies for a wide range of human tumors and represents an important tool in the quest for personalized medicine.

This protocol outlines the generation of human immune system (HIS) mice for immuno-oncology studies. Instructions and considerations in the use of this model for testing human immunotherapeutics on human tumors implanted in this model are presented with an emphasis on characterizing the response of the human immune system to the tumor.

在携带人类肿瘤的人源化小鼠模型中测试癌症免疫疗法

Reversing the immunosuppressive nature of the tumor microenvironment is critical for the successful treatment of cancers with immunotherapy drugs. Murine ...

癌症研究

Humanized NOD/SCID/IL2r&#947;null (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Ethical regulations and technical challenges for research in human pathology, immunology, and therapeutic development have placed small animal models in high demand. With a close genetic and behavioral resemblance to humans, small animals such as the mouse are good candidates for human disease models, through which human-like symptoms and responses can be recapitulated. Further, the mouse genetic background can be altered to accommodate diverse demands. The NOD/SCID/IL2r&#947;null (NSG) mouse is one of the most widely used immunocompromised mouse strains; it allows engraftment with human hematopoietic stem cells and/or human tissues and the subsequent development of a functional human immune system. This is a critical milestone in understanding the prognosis and pathophysiology of human-specific diseases such as HIV/AIDS and aiding the search for a cure. Herein, we report a detailed protocol for generating a humanized NSG mouse model (hu-NSG) by hematopoietic stem cell transplantation into a radiation-conditioned neonatal NSG mouse. The hu-NSG mouse model shows multi-lineage development of transplanted human stem cells and susceptibility to HIV-1 viral infection. It also recapitulates key biological characteristics in response to combinatorial antiretroviral therapy (cART).

This protocol provides a method to establish humanized mice (hu-NSG) via intrahepatic injection of human hematopoietic stem cells into radiation-conditioned neonatal NSG mice. The hu-NSG mouse is susceptible to HIV infection and combinatorial antiretroviral therapy (cART) and serves as a suitable pathophysiological model for HIV replication and latency investigations.

人性化的 nod/scid/il2γ空 (hu-nsg) 小鼠 hiv 复制和延迟研究模型

Ethical regulations and technical challenges for research in human pathology, immunology, and therapeutic development have placed small animal models in ...

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Despite the increased life expectancy of patients infected with human immunodeficiency virus-1 (HIV-1), liver disease has emerged as a common cause of their morbidity. The liver immunopathology caused by HIV-1 remains elusive. Small xenograft animal models with human hepatocytes and human immune system can recapitulate the human biology of the disease&#39;s pathogenesis. Herein, a protocol is described to establish a dual humanized mouse model through human hepatocytes and CD34+ hematopoietic stem/progenitor cells (HSPCs) transplantation, to study liver immunopathology as observed in HIV-infected patients. To achieve dual reconstitution, male TK-NOG (NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(Alb-TK)7-2/ShiJic) mice are intraperitoneally injected with ganciclovir (GCV) doses to eliminate mouse transgenic liver cells, and with treosulfan for nonmyeloablative conditioning, both of which facilitate human hepatocyte (HEP) engraftment and human immune system (HIS) development. Human albumin (ALB) levels are evaluated for liver engraftment, and the presence of human immune cells in blood detected by flow cytometry confirms the establishment of human immune system. The model developed using the protocol described here resembles multiple components of liver damage from HIV-1 infection. Its establishment could prove to be essential for studies of hepatitis virus co-infection and for the evaluation of antiviral and antiretroviral drugs.

This protocol provides a reliable method to establish humanized mice with both human immune system and liver cells. Dual reconstituted immunodeficient mice achieved via intrasplenic injection of human hepatocytes and CD34+ hematopoietic stem cells are susceptible to human immunodeficiency virus-1 infection and recapitulate liver damage as observed in HIV-infected patients.

建立与艾滋病毒相关的肝脏发病机制的双人性化TK-NOG小鼠模型

Despite the increased life expectancy of patients infected with human immunodeficiency virus-1 (HIV-1), liver disease has emerged as a common cause of ...

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Humanized NOD/SCID/IL-2 receptor &#947;-chainnull mice recapitulate some features of human immunity, which can be exploited in basic and pre-clinical research on infectious diseases. Described here are three models of humanized immunodeficient mice for studying the dynamics of HIV infection. The first is based on the intrahepatic injection of CD34+ hematopoietic stem cells in newborn mice, which allows for the reconstitution of several blood and lymphoid tissue-confined cells, followed by infection with a reference HIV strain. This model allows monitoring for up to 36 weeks post-infection and is hence called the chronic model. The second and third models are referred to as the acute and reactivation models, in which peripheral blood mononuclear cells are intraperitoneally injected in adult mice. In the acute model, cells from a healthy donor are engrafted through the intraperitoneal route, followed by infection with a reference HIV strain. Finally, in the reactivation model, cells from an HIV-infected donor under antiretroviral therapy are engrafted via the intraperitoneal route. In this case, a drug-free environment in the mouse allows for virus reactivation and an increase in viral load. The protocols provided here describe the conventional experimental approach for humanized, immunodeficient mouse models of HIV infection.

Described here are three experimental approaches for studying the dynamics of HIV infection in humanized mice. The first permits the study of chronic infection events, whereas the two latter allows for the study of acute events after primary infection or viral reactivation.

人类免疫缺陷小鼠模型中的慢性、急性和再激活HIV感染

Humanized NOD/SCID/IL-2 receptor &#947;-chainnull mice recapitulate some features of human immunity, which can be exploited in basic and pre-clinical ...

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Humanized mice provide a sophisticated platform to study human immunodeficiency virus (HIV) virology and to test antiviral drugs. This protocol describes the establishment of a human immune system in adult NOG mice. Here, we explain all the practical steps from isolation of umbilical cord blood derived human CD34+ cells and their subsequent intravenous transplantation into the mice, to the manipulation of the model through HIV infection, combination antiretroviral therapy (cART), and blood sampling. Approximately 75,000 hCD34+ cells are injected intravenously into the mice and the level of human chimerism, also known as humanization, in the peripheral blood is estimated longitudinally for months by flow cytometry. A total of 75,000 hCD34+ cells yields 20%&#8211;50% human CD45+ cells in the peripheral blood. The mice are susceptible to intravaginal infection with HIV and blood can be sampled once weekly for analysis, and twice monthly for extended periods. This protocol describes an assay for quantification of plasma viral load using droplet digital PCR (ddPCR). We show how the mice can be effectively treated with a standard-of-care cART regimen in the diet. The delivery of cART in the form of regular mouse chow is a significant refinement of the experimental model. This model can be used for preclinical analysis of both systemic and topical pre-exposure prophylaxis compounds as well as for testing of novel treatments and HIV cure strategies.

We have developed a protocol for the generation and evaluation of a humanized and human immunodeficiency virus-infected NOG mouse model based on stem cell transplant, intravaginal human immunodeficiency virus exposure, and droplet digital PCR RNA quantification.

用于阴道内艾滋病毒暴露和艾滋病毒感染的人性化 NOG 小鼠

Humanized mice provide a sophisticated platform to study human immunodeficiency virus (HIV) virology and to test antiviral drugs. This protocol describes ...

Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34+ Cells Injection, and Cytokine Delivery

Animal models provide a vital translation between in vitro and in vivo biomedical research. Humanized mouse models provide a bridge in the representation of human systems, thereby allowing for a more accurate study of pathogenesis, biomarkers, and many other scientific queries. In this method described, immune-deficient NOD-scid IL2R&#947;null (NSG) mice are implanted with autologous thymus, injected with liver-derived CD34+ cells followed by a series of injected cytokine deliveries. In contrast to other models of a similar nature, the model described here promotes an improved reconstitution of immune cells by delivering cytokines and growth factors via transgenes encoded in AAV8 or pMV101 DNA-based vectors. Moreover, it offers long-term stability with reconstituted mice having an average lifespan of 30 weeks after CD34+ injections. Through this model, we hope to provide a stable and impactful method of studying immunotherapy and human disease in a murine model, thus demonstrating the need for predictive preclinical models.

Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34+ Cells Injection, and Cytokine Delivery

Humanized mouse models provide a more accurate representation of the human immune microenvironment. This manuscript describes the process in which these models are created through a renal graft of human thymus, injection of human CD34+ cells, and the targeted delivery of human cytokine transgenes to promote CD34+ cell proliferation and differentiation.

Animal models provide a vital translation between in vitro and in vivo biomedical research. Humanized mouse models provide a bridge in the representation ...

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

The human immunodeficiency virus (HIV-1) pandemic continues to spread unabated worldwide, and currently, there is no vaccine available against HIV. Although combinational antiretroviral therapy (cART) has been successful in suppressing viral replication, it cannot completely eradicate the reservoir from HIV-infected individuals. A safe and effective cure strategy for HIV infection will require multipronged methods, and therefore the advancements of animal models for HIV-1 infection are pivotal for the development of HIV cure research. Humanized mice recapitulate key features of HIV-1 infection. The humanized mouse model can be infected by HIV-1 and viral replication can be controlled with cART regimens. Moreover, cART interruption results in a prompt viral rebound in humanized mice. However, administration of cART to the animal can be ineffective, difficult, or toxic, and many clinically relevant cART regimens are unable to be optimally utilized. Along with being potentially unsafe for researchers, administration of cART by a commonly used intensive daily injection procedure induces stress by physical restraint of the animal. The novel oral cART method to treat HIV-1 infected humanized mice described in this article resulted in suppression of viremia below the detection level, increased rate of CD4+ restoration, and improved overall health in HIV-1 infected humanized mice.

This protocol describes a novel method to deliver oral combinational antiretroviral drugs that successfully suppress HIV-1 RNA replication in humanized mice.

口服联合抗逆转录病毒治疗HIV-1感染人源化小鼠

The human immunodeficiency virus (HIV-1) pandemic continues to spread unabated worldwide, and currently, there is no vaccine available against HIV. ...

Isolating Cord Blood Hematopoietic Stem Cells to Generate Human Immune System Mice

Source: Lanis, J. M., et al. <a href="https://app-jove-com.remotexs.ntu.edu.sg/v/64606">Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors.</a> J. Vis. Exp. (2022)
This video demonstrates a technique for generating human immune system (HIS) mice. CD34+ hematopoietic stem cells (HSCs) are isolated from human cord blood buffy coat cells using antibody-coated magnetic beads. The CD34+ HSCs are expanded in a growth medium enriched with cytokines and cryopreserved. Finally, the thawed HSCs are injected into an immunodeficient mouse pup to establish the HIS mouse model.

分离脐带血造血干细胞以产生人类免疫系统小鼠

All procedures involving sample collection have been performed in accordance with the institute&#39;s IRB guidelines. All procedures involving animal ...

JoVE Encyclopedia of Experiments

Immunology

Immunotherapy

Model Development and Disease Study

Developing a Humanized Mouse Model with Human Liver Cells and Immune Cells

Source: Dagur, R. S. et al., <a href="https://app-jove-com.remotexs.ntu.edu.sg/v/58645">Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis.</a>&#160;J. Vis. Exp.&#160;(2019)
This video demonstrates a method for generating a dual humanized mouse model with a human immune system and liver cells. It involves transplanting human liver cells and hematopoietic stem and progenitor cells into a transgenic immunodeficient mouse via intrasplenic injection, leading to engraftment of liver cells and development of human immune cells.

开发具有人肝细胞和免疫细胞的人源化小鼠模型

All procedures involving animal models have been reviewed by the local institutional animal care committee and the JoVE veterinary review board.
1. ...